Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab vs placebo in idiopathic pulmonary fibrosis (ZEPHYRUS-1 China)
CTR20202271Phase 3Terminated
- Sponsor
- FibroGen
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pamrevlumab in idiopathic pulmonary fibrosis (IPF), sponsored by FibroGen. Started Nov 2020; status: terminated.
02
Drugs
pamrevlumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20202271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202271.